arrow
K

Kevin H.M. Kuo

University of Toronto
H指数:28
被引数:3,274

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Thalassaemia

Publisher Correction: 地中海贫血

2026-10-300
PRE
No difference in alloimmunization of pregnant adults with sickle cell disease exposed to chronic versus on-demand transfusions: A two-center retrospective cohort study

镰状细胞病患者妊娠成人接受慢性输血与按需输血后allo免疫反应无差异:一项两中心回顾性队列研究

2026-10-080
PRE
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3trial

米塔匹泛在依赖输血的α-地中海贫血或β-地中海贫血成人中的有效性和安全性(ENERGIZE-T):一项双盲、随机、多中心、安慰剂对照、III期临床试验

2026-09-121
PRE
Thalassaemia

地中海贫血

2026-07-090
PRE
Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial

在BEYOND试验中,接受 luspaterept 治疗的非输血依赖性β-地中海贫血患者5年治疗期内的患者报告结局

2026-03-010
PRE
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources

新型疗法时代输血依赖性β-地中海贫血的管理:一种基于优先级的矩阵,适用于资源有限的环境

2025-12-310
PRE
Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study

加拿大安大略省镰状细胞病合并复发性血管闭塞性危象患者的临床并发症、死亡率和医疗资源利用情况:一项回顾性队列研究

2025-11-210
OAAI
Improvements in Health-Related Quality of Life in Patients with Transfusion-Dependent β-Thalassemia After Exagamglogene Autotemcel

输血依赖性β-地中海贫血患者在接受Exagamglogene autotemcel治疗后健康相关生活质量改善

2025-08-280
OAAI
Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene Autotemcel

重症镰状细胞病患者在Exagamglogene autotemcel治疗后健康相关生活质量改善

2025-08-280
OAAI
Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease

Rowland通用痴呆评估量表(RUDAS)在镰状细胞病成人患者认知障碍检测中的验证

BLOOD
IF23.1
2024-11-050
PRE
Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II- Results from the 8-Week Dose-Escalation Period

满足:一项Eurobloodnet多中心、单臂II期临床试验,评估米塔吡范在成人红细胞膜病和先天性红细胞生成障碍性贫血II型患者中的应用——8周剂量递增期结果

BLOOD
IF23.1
2024-11-050
PRE